A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.

PURPOSE This study was designed to evaluate the efficacy and safety of single-agent gemcitabine for the treatment of patients with anthracycline- and taxane-pretreated metastatic breast cancer (MBC). Eligible patients were required to have bidimensionally measurable MBC that had been treated with 2-4 prior chemotherapy regimens that included an anthracycline and a taxane. Gemcitabine was delivered at a dose of 800 mg/m2 on days 1, 8, and 15 of a 28-day cycle until evidence of disease progression. PATIENTS AND METHODS Twenty-two patients were enrolled and included in the safety analysis; 18 patients were evaluable for response. The median age of patients was 54 years (range, 36-70 years). The mean number of prior chemotherapy regimens for metastatic disease was 2.3, and the mean dose of gemcitabine delivered was 911 mg/m2 (range, 600-1600 mg/m2). RESULTS Overall, gemcitabine was well tolerated with minimal grade 3 toxicities; the only grade 4 toxicity was 1 case of pulmonary embolus. Three patients had evidence of partial tumor regression (17%; 95% CI, 4%-41%), and 1 patient had a 41% decrease in tumor volume, including liver metastasis. CONCLUSIONS Gemcitabine is active and well tolerated as monotherapy given in heavily pretreated patients with MBC after anthracyclines and taxanes. The activity and safety reported in this trial are consistent with previous reports in similar patients.

[1]  C. Moinpour,et al.  Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): Quality of life (QoL) and pain palliation results from the global phase III study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Nag,et al.  Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall surviva. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Seynaeve,et al.  Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane , 2001, Breast Cancer Research and Treatment.

[4]  M. Blackstein,et al.  Gemcitabine as First-Line Therapy in Patients with Metastatic Breast Cancer: A Phase II Trial , 2002, Oncology.

[5]  L. Zelek,et al.  Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma , 2001, Cancer.

[6]  A. Buzdar,et al.  Multicenter, Phase II study of capecitabine in taxane‐pretreated metastatic breast carcinoma patients , 2001, Cancer.

[7]  M. Espié,et al.  Single-Agent Gemcitabine Is Active in Previously Treated Metastatic Breast Cancer , 2001, Oncology.

[8]  R. Bast,et al.  Phase II study of vinorelbine administered by 96‐hour infusion in patients with advanced breast carcinoma , 1999, Cancer.

[9]  O. Sezer,et al.  Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. , 1999, Anti-cancer drugs.

[10]  O. Sezer,et al.  Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study. , 1999, Anti-cancer drugs.

[11]  K. Possinger,et al.  Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. , 1999, Anti-cancer drugs.

[12]  下山正徳 National Cancer Institute-Common Toxicity Criteria , 1999 .

[13]  E. Kubista,et al.  Second- and third-line treament of metastatic breast cancer with gemcitabine , 1998 .

[14]  R. Livingston,et al.  Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  W. Plunkett,et al.  Gemcitabine: preclinical pharmacology and mechanisms of action. , 1996, Seminars in oncology.

[16]  C. Dittrich,et al.  Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel – a phase II study , 1996, Cancer Chemotherapy and Pharmacology.

[17]  A. Harris,et al.  Advanced breast cancer: a phase II trial with gemcitabine. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.